Last updated on April 2020

Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: LIVER DISEASE | Wilson's Disease | Liver Disorders
  • Age: Between 12 - 100 Years
  • Gender: Male or Female

Inclusion
  • Established diagnosis of Wilson disease by Leipzig-Score = or > than 4
  • 12 years of age or older
  • Female patients of childbearing potential, if heterosexually active, must be willing to follow protocol-specified guidance for highly effective contraception starting at least 6 weeks before Day 1 visit and continuing through 28 days after the last dose of either ALXN1840 or SoC
  • Male patients, if heterosexually active, must be willing to follow protocol-specified guidance for highly effective contraception beginning at Day 1 and continuing through 90 days after last dose of either SoC or ALXN1840
    Exclusion
  • Decompensated hepatic cirrhosis
  • MELD score > 13
  • Modified Nazer score > 7
  • Clinically significant GI bleed within past 3 months
  • Alanine aminotransferase > 2 X upper limit of normal (ULN) for patients treated for > 28 days with WD therapy (Cohort 1)
  • Alanine aminotransferase > 5 X ULN for treatment nave patients or patients who have been treated for < or = to 28 days (Cohort 2)
  • Marked neurological disease requiring either nasogastric feeding or intensive inpatient medical care
  • Hemoglobin < 9 g/dL
  • History of seizure activity within 6 months prior to informed consent
  • Pregnant (or women who are planning to become pregnant) or breastfeeding women
  • Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus or seropositivity for human immunodeficiency virus (HIV)
  • Previous treatment with tetrathiomolybdate
  • Patients with end-stage renal disease on dialysis (CKD 5) or creatinine clearance < 30 mL/min

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.